209 related articles for article (PubMed ID: 22534668)
21. Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer.
Xu L; Huang Y; Chen D; He J; Zhu W; Zhang Y; Liu X
Cancer Genet; 2014 May; 207(5):214-20. PubMed ID: 24906642
[TBL] [Abstract][Full Text] [Related]
22. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
23. Expression of Ras-related protein 25 predicts chemotherapy resistance and prognosis in advanced non-small cell lung cancer.
Ma YF; Yang B; Li J; Zhang T; Guo JT; Chen L; Li M; Chu J; Liang CY; Liu Y
Genet Mol Res; 2015 Oct; 14(4):13998-4008. PubMed ID: 26535714
[TBL] [Abstract][Full Text] [Related]
24. [DDP-sensitivity-related genes in 10 lung cancer cell lines].
Li CH; Cai L; Chen XS; Meng QW; Sui GJ
Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):418-21. PubMed ID: 19024514
[TBL] [Abstract][Full Text] [Related]
25. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
Olaussen KA; Mountzios G; Soria JC
Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
[TBL] [Abstract][Full Text] [Related]
26. Role of 14-3-3σ in resistance to cisplatin in non-small cell lung cancer cells.
Cetintas VB; Tetik A; Cok G; Kucukaslan AS; Kosova B; Gunduz C; Veral A; Eroglu Z
Cell Biol Int; 2013 Jan; 37(1):78-86. PubMed ID: 23339090
[TBL] [Abstract][Full Text] [Related]
27. Wilms' tumor 1 enhances Cisplatin-resistance of advanced NSCLC.
Wu C; Wang Y; Xia Y; He S; Wang Z; Chen Y; Wu C; Shu Y; Jiang J
FEBS Lett; 2014 Dec; 588(24):4566-72. PubMed ID: 25447528
[TBL] [Abstract][Full Text] [Related]
28. Cisplatin resistance induced by decreased apoptotic activity in non-small-cell lung cancer cell lines.
Cetintas VB; Kucukaslan AS; Kosova B; Tetik A; Selvi N; Cok G; Gunduz C; Eroglu Z
Cell Biol Int; 2012 Mar; 36(3):261-5. PubMed ID: 22397496
[TBL] [Abstract][Full Text] [Related]
29. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
[TBL] [Abstract][Full Text] [Related]
30. [Establishment of a human nasopharyngeal carcinoma drug-resistant cell line CNE2/DDP and screening of drug-resistant genes].
Jiang RD; Zhang LX; Yue W; Zhu YF; Lu HJ; Liu X; Cen XT; Guan XY; Li CH
Ai Zheng; 2003 Apr; 22(4):337-45. PubMed ID: 12703984
[TBL] [Abstract][Full Text] [Related]
31. GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin.
Gong X; Liu J; Zhang D; Yang D; Min Z; Wen X; Wang G; Li H; Song Y; Bai C; Li J; Zhou J
PLoS One; 2017; 12(8):e0182410. PubMed ID: 28771580
[TBL] [Abstract][Full Text] [Related]
32. Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12-5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients.
Yu DH; Li JH; Wang YC; Xu JG; Pan PT; Wang L
Clin Chim Acta; 2011 May; 412(11-12):930-5. PubMed ID: 21277290
[TBL] [Abstract][Full Text] [Related]
33. [Prediction of a non-small cell lung cancer sensitivity to cisplatin and paclitaxel based on the marker genes expression].
Boiarskikh UA; Kondrakhin IuV; Evshin IS; Sharipov RN; Komel'kov AV; Musatkina EA; Chevkina EM; Sukoian MA; Kolpakov FA; Kashkin KN; Filipenko ML
Mol Biol (Mosk); 2011; 45(4):652-61. PubMed ID: 21954597
[TBL] [Abstract][Full Text] [Related]
34. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.
Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ
Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469
[TBL] [Abstract][Full Text] [Related]
35. Up-regulation of extracellular signal-regulated kinase 1/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small-cell lung cancer cells.
Ko JC; Tsai MS; Chiu YF; Weng SH; Kuo YH; Lin YW
J Pharmacol Exp Ther; 2011 Jul; 338(1):184-94. PubMed ID: 21444628
[TBL] [Abstract][Full Text] [Related]
36. [Examination of resistance of lung adenocarcinoma cells to cisplatin by technetium-99m methoxyisobutyl isonitrile].
Hu S; Hu CP; Liang CH
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(21):1493-8. PubMed ID: 16061030
[TBL] [Abstract][Full Text] [Related]
37. Preclinical assessment of cisplatin-based therapy versus docetaxel-based therapy on a panel of human non-small-cell lung cancer xenografts.
Némati F; Bras-Gonçalves R; Fontaine JJ; de Pinieux G; De Cremoux P; Chapelier A; Daniel C; Laurent-Puig P; Livartowski A; Judde JG; Bordier V; Poupon MF; Decaudin D
Anticancer Drugs; 2009 Nov; 20(10):932-40. PubMed ID: 19741504
[TBL] [Abstract][Full Text] [Related]
38. The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo.
Nishi M; Abe Y; Fujimori S; Hamamoto A; Inoue Y; Miyazaki N; Oida Y; Ikoma N; Ohnishi Y; Yamazaki H; Ueyama Y; Nakamura M
Oncol Rep; 2005 Aug; 14(2):421-4. PubMed ID: 16012725
[TBL] [Abstract][Full Text] [Related]
39. [Effects of bevacizumab and cisplatin on human lung adenocarcinoma A549/DDP xenografts in nude mice].
Dai M; Luo RC; Zheng DY; Lü CW; Ding XM
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Sep; 27(9):1402-5. PubMed ID: 17884788
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]